Coleman and Company Announces Investment Opinion on Generex Biotechnology Corp.Business Editors NOTE TO EDITORS: The following is an investment opinion issued by Coleman and Company Securities, Inc.: NEW YORK--(BUSINESS WIRE)--April 26, 2000 Generex Biotechnology Corp. (GNBT): Coleman and Co. Reiterates Speculative BUY Coleman and Company Securities, Inc., the New York-based investment banking and brokerage firm, has reiterated its "Speculative Buy" recommendation on Generex Biotechnology Corp. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: GNBT). In a report dated April 25, 2000 by analyst Christopher Moore Christopher Moore may refer to:
n. 1. Orient The countries of Asia, especially of eastern Asia. 2. a. The luster characteristic of a pearl of high quality. b. A pearl having exceptional luster. 3. investors. Generex has developed a proprietary drug delivery platform for the oral administration of large molecule drugs. Its initial focus is the oral delivery of insulin using its proprietary insulin formulation ORALGEN for the treatment of diabetes. Initial Phase II results have shown that ORALGEN provides comparable clinical efficacy to injected in·ject·ed adj. 1. Of or relating to a substance introduced into the body. 2. Of or relating to a blood vessel that is visibly distended with blood. injected 1. introduced by injection. 2. congested. insulin. Generex expects that Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trials will begin in Canada by Q3 2000. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion